Clover Corporation (CLV) H2 2026 earnings summary

Executive summary

• Achieved record FY26 revenue of AUD 97.4 million, up 13% year-over-year, exceeding guidance, with NPAT rising 50% to AUD 10.5 million, driven by strong ARA sales, new products, and improved operating performance.

• Gross margin improved to 35.5%, up 4 percentage points, supported by product mix, innovation, and vertical integration.

• EBITDA rose to AUD 17 million, up AUD 4.7 million (+39%), with margin expansion and stable tax rate.

• Declared a final fully franked dividend of AUD 0.0125 per share.

• Strategic investments in inventory, new product development, and US nutraceutical market expansion underpin long-term growth.

Financial highlights

• Revenue grew 13% year-over-year to AUD 97.4 million, surpassing guidance.

• Gross margin reached 35.5%, a 4% improvement from 30.5% prior year.

• EBITDA: AUD 17 million (up AUD 4.7 million, +39%), EBITDA margin 17.5%.

• NPAT: AUD 10.5 million (up 50%), EPS 6.3c.

• Net working capital increased to AUD 49.8 million, mainly due to higher inventory levels.

Outlook and guidance

• Entering FY27 with positive momentum, expecting first-half revenue ahead of the prior corresponding period.

• Continued investment in new product development, especially CholineXcel, and US nutraceutical market entry.

• Anticipates gradual increase in expenses as US market strategy is enacted.

• CholineXcel expected to see limited release in FY27, with broader sales anticipated from FY28.

• Significant investment planned for new product commercialisation and innovation.